Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (2.795.346 €): Bekämpfung des CardioRenal-Syndroms: auf dem Weg zu einer integrativen Analyse zur Verringerung der Herz-Kreislauf-Belastung bei chronischen Nierenerkrankungen Hor 28.08.2017 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Bekämpfung des CardioRenal-Syndroms: auf dem Weg zu einer integrativen Analyse zur Verringerung der Herz-Kreislauf-Belastung bei chronischen Nierenerkrankungen
Successfully combatting a complex disease requires multi-disciplinary and methodically well-trained scientists. CaReSyAn strives to accomplish exactly this: we will train scientists to successfully integrate proteomics, clinical, experimental and bioinformatical analyses to enhance the understanding, diagnosis and therapy of the cardiorenal syndrome (CRS). CRS comprises disorders of the heart, vessels and kidneys, including the increased development of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). With ~45% of all deaths in CKD patients caused by CVD, the socio-economic burden of CRS is extremely high. CaReSyAn will train scientists in a close cooperation between academia, SME and industry partners. Key objectives are to provide: 1) Excellent scientific training on CRS pathology, integrating clinical/mechanistic knowledge with technological skills (animals and in vitro, molecular and functional studies, proteomics and bioinformatics) to generate innovative insights triggering the understanding, diagnosis and treatment of the CRS; 2) Excellent complementary skills in personal and career development as well as business training required to extend beyond scientific research; and 3) Exposure to both academic and non-academic environments, required to build bridges between researchers and entrepreneurs and support the future translation of research findings in innovative products and services. CaReSyAn builds on already available patient cohorts, advanced technologies and established cooperations. CaReSyAn is complementary to ongoing European programs focusing solely on CKD or CVD and strives to synergistically improve structural training on European level. CaReSyAn will nurture the development of young, broadly-trained scientists able to successfully bridge clinical with basic research as well as academia and industry. This is a cornerstone in effectively combatting complex diseases as CRS, a major killer of this century.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Bayer Pharma AG | ? |
| DSM Materials Science Center B.V. | 0,00 € |
| Idryma Iatroviologikon Ereunon Akademias Athinon | 242.387 € |
| Institut National de la Sante et de la Recherche Medicale | 262.876 € |
| Karolinska Institutet | 263.659 € |
| Medizinische Universitaet Wien | 255.934 € |
| Mosaiques Diagnostics GmbH | 249.216 € |
| RD Nephrologie SAS | 0,00 € |
| Universitaetsklinikum Aachen | 747.649 € |
| Universite de Montpellier | 262.876 € |
| Universiteit Maastricht | 510.749 € |
Quelle: https://cordis.europa.eu/project/id/764474
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: Bayer Pharma AG, Berlin.